SCHEMBL376434

SCHEMBL376434

N=C(NS(=O)(=O)c1ccc(Cl)c([N+](=O)[O-])c1)c1ccc(N2CCN(CC=C(c3ccccc3)c3ccccc3)CC2)cc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BCL2L1 Q07817 10/20 0.46
BCL2 P10415 5/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
ALDH1A1 P00352 2/20 0.44
LMNA P02545 2/20 0.42
GAA P10253 1/20 0.42
VCAM1 P19320 2/20 0.42
MAPT P10636 2/20 0.41
TP53 P04637 1/20 0.41
HTT P42858 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
CTSK P43235 1/20 0.41
KDM4E B2RXH2 1/20 0.40
SLC25A1 P53007 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL376604 0.90 BCL2L1 (0.46) BCL2L1BCL2MEN1KMT2ASMN1; SMN2
SCHEMBL376435 0.84 ALDH1A1 (0.52) BCL2L1BCL2MEN1KMT2ASMN1; SMN2
SCHEMBL13503908 0.84 ALDH1A1 (0.52) BCL2L1BCL2MEN1KMT2ASMN1; SMN2
SCHEMBL376619 0.84 BCL2L1 (0.64) BCL2L1BCL2
SCHEMBL3601748 0.82 BCL2L1 (0.64) BCL2L1BCL2
SCHEMBL376605 0.78 BCL2L1 (0.71) BCL2L1BCL2
SCHEMBL3590505 0.78 BCL2L1 (0.67) BCL2L1BCL2
SCHEMBL431065 0.78 BCL2L1 (0.58) BCL2L1BCL2
SCHEMBL1741520 0.77 BCL2L1 (0.52) BCL2L1BCL2ALDH1A1LMNAGAA
SCHEMBL376602 0.74 ALDH1A1 (0.42) BCL2L1BCL2MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1765778-B1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS ABBOTT LAB (US) 2012-01-25 EP disclosed
US-20100035879-A1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES 2010-02-11 US disclosed
US-7585858-B2 N-sulfonylcarboximidamide apoptosis promoters ABBOTT LABORATORIES (US) 2009-09-08 US disclosed
US-20050272744-A1 N-sulfonylcarboximidamide apoptosis promoters ABBVIE INC. 2005-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035879-A1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS BAX, BCL2, BAD BCL2L1 18/4885BCL2 2/4885MEN1 4383/4885
US-20050272744-A1 N-sulfonylcarboximidamide apoptosis promoters BAX, BCL2, BAD BCL2L1 18/4885BCL2 2/4885MEN1 4383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.